Health Robotics Reports 106 Total New Sales in 2012, Including 27 New Sales in 4Q, Beating FY2011 Record
BOZEN, Sud-Tirol, Italy, February 14, 2013 /PRNewswire/ --
For FY2012 Health Robotics today reported 39 new Robot sales [22 for Oncology, and 17 for non-hazardous IVs] plus 67 i.v.SOFT workflow software contracts, making 2012 yet another record year. For 4Q2012, the company reported 27 new contracts, including 11 I.V. Robots (5 for Oncology Therapy, and 6 for non-hazardous IVs) and 16 i.v.SOFT workflow software agreements, continuing its 4-year supremacy of the world's Sterile Compounding Automation market. Now reaching over 350 total installations in the world [including over 90% of Oncology IV Robots global market share, and over 80% of total IV Robots global market share], Health Robotics continued to benefit in 2012 from its transition to a direct sales and service approach, now accounting for the majority of its gross revenues and profits.
Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "I'm very pleased with 2012 results, especially considering my 5-month medical leave of absence, and the effects of global economic crisis in some regions of the world. Auspiciously, Health-System pharmacists continue to recognize the undeniable fact that Health Robotics' second generation modular architecture of integrated and networked medical devices are fully automated, offer 3 to 4 times faster speed/throughput, for less than half the price, size, and weight than any of its global competitors, and delivering payback periods/R.O.I. of less than 1 year."
During last quarter, Health Robotics and/or some of its global partners signed up 27 new installations under contract at: Brigham & Women's Hospital, LeeSar Sterile Compounding Center (Florida), University of Tennessee Medical Center, University of Chicago Hospital, Hospital of the University of Pennsylvania, University Hospital of Ghent (Belgium), Goes Scheldezoom (Netherlands), Hamad Medical Corporation' Al-Wakrah Hospital (Qatar), King Khaled Hospital of the Ministry of Health (Hail, Saudi Arabia), and Etlik Hospital (Turkey), amongst others.
Mr. DeViedma concluded: "Health Robotics' 4Q and full year performance reflects a healthy mix of additional Robot and IV workflow sales to its pre-existing customers, as well as new sales to new Health-System pharmacies. Of particular interest to me is the expansion into Saudi Arabia and Qatar by replacing Olayan-AHCSC due to its poor service record and customer complaints, the explosion in i.v.SOFT contracts in USA and Benelux, and finally the replacement of CytoCare with the launch of i.v.STATION ONCO in selected countries where syringes and IV Bags are the norm, instead of the IV Bottles still supported by the CytoCare robot."About Health Robotics:
Founded in 2006 and now reaching over 80% total IV Robots market share in the world [including over 90% of the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 350 hospital installations in 5 continents with the only fully-integrated robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies,] to greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput, and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug and diluent exchange errors, improve drug potency, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com
1. Competitors: Intelligent Hospital Systems/RIVA, Fresenius Kabi/MDS, Baxter/Baxa, and Loccioni.
2. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
3. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde . St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
For additional information, please contact:
SOURCE Health Robotics
More by this Source
Health Robotics Appoints Gordon Meyer to Board of Directors
May 01, 2013, 08:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.